Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab vs Chemotherapy in Recurrent Ovarian Clear Cell Carcinoma
NCT03405454Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Oct 2017
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in ovarian clear cell carcinoma (OCCC), sponsored by National University Hospital. Status: unknown.
02
Drugs
durvalumab
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT03405454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405454.